B7 homolog 3 in pancreatic cancer

Table 1 Preclinical studies involving B7 homolog 3-targeting agents in pancreatic cancer

Ref.	Agent/drug	Study models
Lutz et al[101]	Fc-optimized mAb B7-H3-SDIE	In vitro PDAC model
Kasten et al[103]	B7-H3-specific mAb 376.96 conjugated with 212Pb	PDAC in vitro and PDX models
Scribner et al[104] and Wittwer et al[105]	MGC0181 (alone or combined with an anti-PD-1 agent)	PC PDX and immunocompetent mouse models
Lutz et al[114]	B7-H3xCD3 bsAb CC-3	In vitro hepatic, gastric, and PDAC models
You et al[115]	B7-H3x4-1BB2 bsAb	In vitro models of PC and other solid tumors

¹Also known as vobramitamab duocarmazine, an antibody-drug conjugate comprised of a humanized B7 homolog 3 monoclonal antibody conjugated via a cleavable linker to the prodrug seco-duocarmycin hydroxybenzamide azaindole.

²Costimulatory receptor that belongs to the tumor necrosis factor receptor superfamily, broadly expressed on immune cells.

mAb: Monoclonal antibody; bsAb: Bispecific antibody; PC: Pancreatic cancer; PD-1: Programmed cell death protein 1; PDAC: Pancreatic ductal adenocarcinoma; PDX: Patient-derived xenograft; B7-H3: B7 homolog 3.